Company intelligence / Profile preview
Qurient Co., Ltd.
Seongnam-si, Gyeonggi-do, South Koreaqurient.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Qurient has multiple clinical-stage assets. Q301 (topical 5LO inhibitor) is in Phase II for atopic dermatitis. Telacebec (Q203), a Cyt bc1 inhibitor, is in Phase II for mycobacterial infections including tuberculosis. Adrixetinib (Q702), an Axl/Mer/CSF1R inhibitor, completed Phase I for solid tumors and has entered further studies including combinations with KEYTRUDA®. Q901, a selective CDK7 inhibitor for solid tumors, received US FDA approval to begin phase I/II studies[3][2].
- Therapeutic areas
- OncologyDermatologyInfectious Diseases
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
TB Alliance – exclusive license agreement to develop/commercialize Telacebec(Q203)[2]MSD/Merck – collaboration on combination trials of Q702 and KEYTRUDA® as well as evaluation of CDK7 inhibitor Q901 with KEYTRUDA®[2]
Beyond the preview
Go deeper on Qurient Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qurient Co., Ltd..